Navigation Links
FDA Approves Erbitux to Treat Late-stage Head and Neck Cancer
Date:11/7/2011

SILVER SPRING, Md., Nov. 7, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Erbitux (cetuximab) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Combined with chemotherapy, Erbitux extended the lives of those receiving the treatment combination compared with those receiving chemotherapy alone. Erbitux already is FDA-approved for certain types of colon cancer, and has been approved since 2006 for treatment of non-metastatic head and neck cancer in combination with radiation therapy (first-line) or as a single agent (following standard treatment).

According to the National Cancer Institute, head and neck cancers account for 3 percent to 5 percent of all cancers in the United States. These cancers typically develop in the nose, throat or mouth and they are more common in men and in people older than 50.

"Erbitux's ability to extend the lives of patients with head and neck cancers is an important tool for oncologists who often rely on a multi-treatment approach for patients," said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Drug Products in the FDA's Center for Drug Evaluation and Research." Given the aggressive nature of head and neck cancers that cannot be treated with surgery and radiation, it is important that patients have as many treatment options available as possible."

The safety and effectiveness of Erbitux for this indication is based on the results of a multi-center clinical study conducted outside the United States involving 442 patients with metastatic or recurrent head and neck cancer. The study used a non-U.S. approved version of cetuximab, rather than the U.S.-approved formulation.

Participants had inoperable or widespread disease and had not received prior chemotherapy. Half
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Xarelto to Prevent Stroke in People With Common Type of Abnormal Heart Rhythm
2. FDA Approves U.S. Market Return for octagam® Following Octapharmas Implementation of Enhanced Safety Measures
3. FDA Approves First Artificial Aortic Heart Valve Placed Without Open-Heart Surgery
4. FDA Approves First Generic Olanzapine to Treat Schizophrenia, Bipolar Disorder
5. FDA Approves Onfi To Treat Severe Type of Seizures
6. FDA Approves Longer Duration Efficacy and Safety for EUFLEXXA®
7. FDA Approves Label Update for PREZISTA® to Include 192-Week Data in HIV-1-Infected Adult Patients Starting Treatment
8. FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body
9. FDA Approves Combination Therapy Juvisync
10. FDA Approves Cialis to Treat Benign Prostatic Hyperplasia
11. FDA Approves Remicade to Treat Ulcerative Colitis in Children Older Than 6 Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: ... registered offering of common shares in the ... Offering, the Company issued 7,286,432 common shares at a ... of approximately $1.45 billion. On March 18, 2015, the ... a final prospectus supplement to its effective shelf registration ...
(Date:3/27/2015)... 27, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... today announced that they have entered into ... and proprietary sd-rxRNA® technology for use in ... has the potential to result in novel, ... that could be a significant step toward ...
(Date:3/27/2015)... , March 27, 2015  WebMD ... leading source of health information, today announced ... new National Action Plan for Combating ... Obama emphasized the urgency and importance of ... national and global health.    The ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3
... -- Weikang Bio-technology Group, Inc. (the "Company," "Weikang" or ... all of its management departments into the building it ... Chengde Street in the Daowai District of Harbin, the ... of the building. Mr. Yin Wang, the ...
... Dec. 27, 2011  PharmacoFore, Inc., a privately held biopharmaceutical ... equity financing from Founders Fund and the addition ... Board of Directors.   PharmacoFore uses innovative ... treating a variety of conditions related to the ...
Cached Medicine Technology:Weikang Bio-technology Group, Inc. Completes HQ Relocation After Purchasing Building for $14 Million and Answers Questions About its Third Quarter Financials 2Weikang Bio-technology Group, Inc. Completes HQ Relocation After Purchasing Building for $14 Million and Answers Questions About its Third Quarter Financials 3PharmacoFore, Inc. Secures $10 Million in Equity Financing From Founders Fund 2
(Date:3/28/2015)... ARDX will sponsor the 7th Annual Women’s Wellness ... Chesapeake Conference Center in Chesapeake, Virginia. Each year, ARDX ... women in the Hampton Roads region. The 2015 Women’s ... Women grow stronger through sharing their stories and learning ... the WWC™ theme is T-talk where we will share a ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Servpro ... , this week released a report about the link ... of asthma sufferers, and according to recent medical research, ... , According to the Environmental Protection Agency, people with ... reactions. Breathing in mold may trigger asthma attacks for ...
(Date:3/27/2015)... The Monogamy Method - a new ... Jason Rogers has just been released to the public ... surrounding the course's launch has caught the attention of ... review of the new program. , "Many women report ... suddenly start pulling away or expressing interest in other ...
(Date:3/27/2015)... 2015 In her mid-forties and with a ... working, Monica K. arrived at JET Uniform & Supply ... defensive and scared. The owners and staff at JET, which ... (EPSS) to offer jobs to challenged residents like Monica, were ... willingness to begin with the end in mind,” says Stephen ...
(Date:3/27/2015)... New York, New York (PRWEB) March 27, 2015 ... lawsuits ( http://www.lipitorlawsuitcenter.com/ ) that allege the statin medication ... 2 diabetes has granted Pfizer Inc.’s Motion to Dismiss ... proceeding. According to a Case Management Order issued in ... March 23rd, the Court determined that the dismissals were ...
Breaking Medicine News(10 mins):Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3
... have received grants from the California Institute for Regenerative ... treating diabetes and brain tumors. The intent of ... applications to the U.S. Food and Drug Administration within ... The two grants, awarded to collaborative scientific teams, total ...
... statins protect heart during infection , THURSDAY, Oct. 29 (HealthDay ... also help prevent death from severe flu, a new study ... evidence suggests that statins -- which include medicines such as ... infections. Whether they help with flu, however, has been more ...
... Oct. 29 Abbott (NYSE: ABT ) announced ... Improvement Award for environmental excellence. It is the ... efforts to safeguard the environment and integrate sustainability initiatives ... Illinois are an important part of our broader work ...
... WASHINGTON, Oct. 29 Bread for the World President Rev. ... Africa and Global Health to make ending hunger, child and ... an empowered, distinct development voice their top priorities. , ... this morning during a hearing in Congress. He said that ...
... therapies, which claim to use subtle energy to stimulate ... reducing the intensity of pain in a number of ... behaviors in dementia, over and above what standard treatments ... Shamini Jain, from the UCLA Division of Cancer Prevention ...
... 29 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ... of compounds for the treatment of cardiovascular and ... Senior Vice President Research & Development will present ... Disease", and will discuss the Company,s cardio-metabolic product ...
Cached Medicine News:Health News:UCSF diabetes, brain tumor stem cell grants to drive development of therapies 2Health News:UCSF diabetes, brain tumor stem cell grants to drive development of therapies 3Health News:UCSF diabetes, brain tumor stem cell grants to drive development of therapies 4Health News:Cholesterol Drugs May Help Prevent Flu Deaths 2Health News:Abbott Receives Sustainability Award for Continued Efforts to Protect the Environment in Illinois 2Health News:Abbott Receives Sustainability Award for Continued Efforts to Protect the Environment in Illinois 3Health News:Bread for the World Urges House Committee to Support U.S. Global Hunger Initiative 2Health News:Biofield therapies: Helpful or full of hype? 2Health News:VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference 2Health News:VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference 3Health News:VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference 4Health News:VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference 5
... and probe system used together to quantify ... based system is a sandwich nucleic acid ... for RNA detection and quantification, by amplifying ... technology. Branched DNA allows immediate quantification of ...
Xsera Rapid HIV-1/2 Antibody Controls are unassayed positive and negative quality control materials used for monitoring the performance of qualitative rapid HIV-1 and HIV-2 test kits....
...
For the qualitative detection of Infectious mononucleosis IgM heterophile antibodies in human whole blood, serum and plasma specimens....
Medicine Products: